{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"77"}]}],"title":"ALKP, Any Increase, n=123, 237"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"7"}]}],"title":"ALKP, Increase to Grade 3, n=123, 237"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"ALKP, Increase to Grade 4, n=123, 237"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"110"}]}],"title":"ALT, Any Increase, n=123, 237"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"18"}]}],"title":"ALT, Increase to Grade 3, n=123, 237"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"}]}],"title":"ALT, Increase to Grade 4, n=123, 237"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"122"}]}],"title":"AST, Any Increase, n=123, 239"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"13"}]}],"title":"AST, Increase to Grade 3, n=123, 239"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"}]}],"title":"AST, Increase to Grade 4, n=123, 239"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"81"}]}],"title":"Albumin, Any Increase, n=123, 239"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"title":"Albumin, Increase to Grade 3, n=123, 239"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Albumin, Increase to Grade 4, n=123, 239"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"28"}]}],"title":"Creatinine, Any Increase, n=123, 239"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Creatinine, Increase to Grade 3, n=123, 239"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Creatinine, Increase to Grade 4, n=123, 239"},{"categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"106"}]}],"title":"Hyperglycemia, Any Increase, n=122, 238"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"title":"Hyperglycemia, Increase to Grade 3, n=122, 238"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Hyperglycemia, Increase to Grade 4, n=122, 238"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"37"}]}],"title":"Hyperkalemia, Any Increase, n=123, 238"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}],"title":"Hyperkalemia, Increase to Grade 3, n=123, 238"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Hyperkalemia, Increase to Grade 4, n=123, 238"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"10"}]}],"title":"Hypernatremia, Any Increase, n=123, 238"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Hypernatremia, Increase to Grade 3, n=123, 238"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Hypernatremia, Increase to Grade 4, n=123, 238"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"21"}]}],"title":"Hypoglycemia, Any Increase, n=122, 238"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Hypoglycemia, Increase to Grade 3, n=122, 238"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Hypoglycemia, Increase to Grade 4, n=122, 238"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"32"}]}],"title":"Hypokalemia, Any Increase, n=123, 238"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"}]}],"title":"Hypokalemia, Increase to Grade 3, n=123, 238"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Hypokalemia, Increase to Grade 4, n=123, 238"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"74"}]}],"title":"Hyponatremia, Any Increase, n=123, 238"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"9"}]}],"title":"Hyponatremia, Increase to Grade 3, n=123, 238"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Hyponatremia, Increase to Grade 4, n=123, 238"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"68"}]}],"title":"Total Bilirubin, Any Increase, n=122, 237"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}],"title":"Total Bilirubin, Increase to Grade 3, n=122, 237"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Total Bilirubin, Increase to Grade 4, n=122, 237"}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"239"}],"units":"Participants"}],"description":"Shifts in clinical chemistry values by grade were summarized based on the NCI CTCAE Version 3.0. Participants with a missing baseline grade were assumed to have a baseline Grade of 0. Any increase in grade from baseline and shifts to Grade 3 and 4 at any point in the study after baseline are reported. alkaline phosphatase, ALKP; alanine aminotransferase, ALT; aspartate aminotransferase, AST. Hyper/hypoglycemia refers to high/low glucose; hyper/hypokalemia refers to high/low potassium; hyper/hyponatremia refers to high/low sodium.","groups":[{"description":"Matching placebo tablets administered orally once daily for a duration until participants experienced disease progression, death, unacceptable toxicity, or participants withdrew consent","id":"OG000","title":"Placebo"},{"description":"Pazopanib 200 milligrams (mg) and 400 mg film-coated tablets (containing pazopanib monohydrochloride) administered orally at a dose of 800 mg once daily for a duration until participants experienced disease progression, death, unacceptable toxicity, or participants withdrew consent","id":"OG001","title":"Pazopanib"}],"paramType":"NUMBER","populationDescription":"Safety Population. Data were analyzed for participants who were on-therapy and provided data at the indicated time point.","reportingStatus":"POSTED","timeFrame":"From baseline (Day 1) until study drug discontinuation or end of treatment (assessed for an average of 20 weeks)","title":"Number of Participants With the Indicated Grade Shifts From Baseline Grade for Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, Albumin, Creatinine, Hyper/Hypoglycemia, Hyper/Hypokalemia, Hyper/Hyponatremia, and Total Bilirubin","type":"SECONDARY","unitOfMeasure":"participants"}